Fundraising Fox
Amber
4 known investors
Find your way into Amber
Sign up to find every way you can get introduced to Amber
- Your email: who you already know at Amber, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Amber team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Amber Bio is a biotechnology company developing a novel RNA writing platform capable of multi-kilobase gene edits that can treat multiple mutations across patients with a single product.
Founders & leadership
JB
Jacob Borrajo, PhDFounder and CEO
Investors · 4
Playground Global✓ confirmed by AmberPalo Alto · $1M – $20M
How we know: the company's own site · Playground Global's portfolio page · funding news · press coverage · the VCSheet dataset · Not right? Tell us
Andreessen Horowitzlisted by Andreessen HorowitzMenlo Park · $500K – $50M
How we know: a16z's portfolio · press coverage · Not right? Tell us
Hummingbird Ventureslisted by Hummingbird VenturesSingapore · $500K – $10M
How we know: Hummingbird Ventures's portfolio page · the VCSheet dataset · Not right? Tell us
Related companies · 6
Transition BioTransition Bio applies methods from physics, chemistry, biology, and machine learning to study protein biophysics—including protein aggregation, self-assembly, and protein-protein interactions—for developing therapeutics targeting health and disease. The company is a platform-based biotherapeutics developer founded on academic research from the University of Cambridge.
BridgebioBridgeBio develops treatments for genetic conditions and cancers using a decentralized hub-and-spoke model, where autonomous teams focus on specific diseases or drug candidates while a central hub provides clinical, regulatory, and commercial support. The company partners with academic institutions to advance early-stage research toward late-stage clinical trials.
Amber TherapeuticsAmber Therapeutics develops medical technology focused on treating mixed urinary incontinence, advancing toward pivotal clinical trials in the US with expanded feasibility studies in Europe.
Engage BioEngageBio develops DNA-based medicines using proprietary non-viral delivery technology to achieve extended therapeutic expression from a single dose with low manufacturing complexity.
Cambrian BioCambrian Bio is a clinical-stage drug development company creating precision therapeutics that target metabolic pathways which decline with age, such as AMPK and mTOR. Its lead asset, ATX-304, is an AMPK Network Activator being developed for obesity and prediabetes.
bioBIO is the world's largest advocacy association representing biotechnology companies and research institutions across the United States and 30+ other nations. The organization facilitates industry networking through events, conferences, and partnering software while providing cost-savings programs and advocacy services for member companies.
Companies working in the same space as Amber.
In the news
Frequently asked questions
- What does Amber do?
- Amber Bio is a biotechnology company developing a novel RNA writing platform capable of multi-kilobase gene edits that can treat multiple mutations across patients with a single product.
- Who founded Amber?
- Amber was founded by Jacob Borrajo, PhD.
- Who are Amber's investors?
- Amber's investors include Playground Global, Andreessen Horowitz, Hummingbird Ventures, Pillar VC.